002365 Qianjiang Yongan Pharmaceutical
- 7.10
- -0.08-1.11%
Qianjiang Yongan Pharmaceutical News
Qianjiang Yongan Pharmaceutical (002365.SZ): First buyback of 151,900 shares, involving 1.1082 million yuan.
On June 5th, Gelunhui reported that Qianjiang Yongan Pharmaceutical (002365.SZ) announced that on June 5th, 2024, the company repurchased 151,900 shares of company stock through centralized bidding transactions for the first time, and the repurchased shares accounted for 0.05% of the company's total share capital. The highest transaction price was 7.30 yuan/share, the lowest transaction price was 7.28 yuan/share, and the total transaction amount was 1,108,173.00 yuan (excluding transaction fees). The repurchase is in compliance with relevant laws and regulations and conforms to the established stock repurchase plan.
Qianjiang Yongan Pharmaceutical (002365.SZ): has not yet repurchased shares.
On June 4th, Gelunhui reported that as of May 31st, 2024, Qianjiang Yongan Pharmaceutical (002365.SZ) had not yet repurchased any shares.
Qianjiang Yongan Pharmaceutical's (SZSE:002365) Five-year Decline in Earnings Translates Into Losses for Shareholders
This week we saw the Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE:002365) share price climb by 19%. But that doesn't change the fact that the returns over the last five years have been less than
Yongan Pharmaceutical (002365.SZ): Net profit of 28.68 million yuan in the first quarter increased 91.42% year-on-year
On April 29, Ge Longhui | Yongan Pharmaceutical (002365.SZ) released its first quarter report. Operating revenue was 197 million yuan, down 36.80% year on year, net profit of 28.68 million yuan, up 91.42% year on year, after deducting non-net profit of 1997 million yuan, up 247.61% year on year, with basic earnings of 0.0973 yuan per share.
Yongan Pharmaceutical (002365.SZ) has been re-certified as a high-tech enterprise
Gelonghui, April 23 | Yongan Pharmaceutical (002365.SZ) announced that the company recently received the “High-tech Enterprise Certificate” jointly issued by the Hubei Provincial Department of Science and Technology, the Hubei Provincial Department of Finance, and the Hubei Provincial Taxation Bureau of the State Administration of Taxation, and the company passed the new certification as a high-tech enterprise. The certificate number is GR202342010015, the date of issue is October 26, 2023, and is valid for three years.
Yongan Pharmaceutical (002365.SZ) announced its 2023 annual results, changing from profit to loss of RMB 12.312,600
Yongan Pharmaceutical (002365.SZ) released its 2023 annual report. During the reporting period, the company achieved an operating income of 9...
Yongan Pharmaceutical (002365.SZ): The main product taurine has a wide range of applications and has been used in cosmetics
Gelonghui, Feb. 22 | Yongan Pharmaceutical (002365.SZ) said on the investor interactive platform that the company and its subsidiaries are mainly engaged in four types of business, one is R&D, production and sales of taurine products; the second is the production and sale of ethylene oxide and R&D, production and sales of related products such as polycarboxylic acid water reducing agent monomers, water reducing agents, etc.; the third is health food R&D, production and sales, and foreign health food imports and sales; four is equity or industrial investment related to the health sector, and the use of some idle funds for cash management, etc. The company's main product, taurine, has a wide range of applications and has been used in cosmetics;
Yongan Pharmaceutical (002365.SZ): As of February 8, 2024, the number of shareholders of the company was 26,645
Gelonghui February 22丨Yongan Pharmaceutical (002365.SZ) said on the investor interactive platform that as of February 8, 2024, the number of shareholders of the company was 26,645.
Yongan Pharmaceutical (002365.SZ): Received a final judgment approved by a judge in the United States District Court for the District of Delaware
Gelonghui, Feb. 6 | Yongan Pharmaceutical (002365.SZ) announced that recently, the company received a final judgment approved by the US Delaware District Court judge, and the company won the case. The main content of the judgment is as follows: The original defendants stipulated and hereby agreed to make this final judgment, that is, Yongan Pharmaceutical's alleged processes and products did not directly or indirectly infringe any of the rights claims of US patents No. 9745258, 9815778, and No. 9926265. According to the court's penalty ruling (Files No. 299 and No. 308), the plaintiff was unable to seek under section 295 of Book 35 of the United States Code
Benign Growth For Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE:002365) Underpins Stock's 27% Plummet
Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE:002365) shareholders that were waiting for something to happen have been dealt a blow with a 27% share price drop in the last month. Instead of being
Yongan Pharmaceutical (002365.SZ): Pre-loss of 5.614 million yuan to 10.526,200 yuan in 2023
Gelonghui, January 30 | Yongan Pharmaceutical (002365.SZ) announced its 2023 annual results forecast. The net profit loss attributable to shareholders of listed companies during the reporting period was 5.614 million yuan - 10.5262 million yuan, profit of 14,03.491 million yuan for the same period last year; net profit loss after deducting non-recurring profit and loss of 688.576 million yuan - 73.698 million yuan, profit of 122.356 million yuan for the same period last year; basic earnings loss per share was 0.0191 yuan/share - 0.0357 yuan/share. During the reporting period, the sales price of the company's main product, taurine, dropped sharply, even though the company
Yongan Pharmaceutical (002365.SZ): Received 2 utility model patent certificates
Gelonghui, January 25 | Yongan Pharmaceutical (002365.SZ) announced that recently, Qianjiang Yongan Pharmaceutical Co., Ltd. received two utility model patent certificates issued by the State Intellectual Property Office, namely a taurine decolorizing filter system and a recycling production system for ammonia-containing materials in the taurine production process.
Yongan Pharmaceutical (002365.SZ): Signed a 2024 equipment manufacturing and system integrated supply framework agreement with Zhejiang Twins
Gelonghui, January 11 | Yongan Pharmaceutical (002365.SZ) announced that the company (“Party A”) plans to sign a framework agreement with Zhejiang Twin Intelligent Equipment Co., Ltd. (“Zhejiang Shuangzi” or “Party B”) to provide equipment manufacturing and system integration services to Zhejiang Twin Company and its holding subsidiaries in 2024. The total transaction amount is not more than RMB 10 million, and the agreement is valid for one year. The chairman of the company, Mr. Chen Yong (related natural person), is a director of Zhejiang Twin, and the company holds 18.3333% of Zhejiang Shuangzi's shares. Therefore, the transaction between the company and Zhejiang Shuangzi forms a related transaction.
Yongan Pharmaceutical (002365.SZ): Subsidiary Yongan Kangjian's existing products are mainly taurine powder and easy to use health food series
Gelonghui, November 17|Yongan Pharmaceutical (002365.SZ) stated on the investor interactive platform that its subsidiary Yongan Kangjian's current products are mainly taurine powder and the E-Ga series of health food products, such as E-Ga-Ne Caffeine, Vitamin B Effervescent Granules, E-Ga-Nan Taurine Vitamin B Effervescent Tablets, etc.
Yongan Pharmaceutical (002365.SZ): Lingan Technology has obtained 6 utility model patent certificates
Gelonghui November 7 | Yongan Pharmaceutical (002365.SZ) announced that recently, Hubei Ling'an Technology Co., Ltd. (“Ling'an Technology” for short), a holding subsidiary of Qianjiang Yongan Pharmaceutical Co., Ltd., received six utility model patent certificates issued by the State Intellectual Property Office.
Yongan Pharmaceutical (002365.SZ) released results for the first three quarters, with net profit of 464.276 million yuan, a year-on-year decrease of 71.28%
Yongan Pharmaceutical (002365.SZ) released its report for the first three quarters. During the reporting period, the company achieved operating income of 8.03...
Yongan Pharmaceutical (002365.SZ): Net profit fell 51.86% in the first half of the year to 56.1263 million yuan
Glonghui, August 23: Yongan Pharmaceutical (002365.SZ) announced its 2023 semi-annual report. Operating income for the reporting period was 578 million yuan, down 30.05% year on year; net profit attributable to shareholders of listed companies was 56.1263 million yuan, down 51.86% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 12.1649 million yuan, down 88.82% year on year; basic earnings per share were 0.19 yuan.
Qianjiang Yongan Pharma Patents Purification Method For Taurine Mother Liquor in Europe, Indonesia
Qianjiang Yongan Pharmaceutical (SHE:002365) has patented a method and system for purifying taurine mother liquor in Europe and Indonesia, according to a filing on Wednesday. Taurine mother liquor is
Yongan Pharmaceutical (002365.SZ) issued an advance reduction. Net profit for the first half of the year is expected to drop 50%-55% from 52.4665 million yuan to 58.2961 million yuan
According to the Zhitong Finance App, Yongan Pharmaceutical (002365.SZ) released its 2023 semi-annual results forecast. Net profit attributable to shareholders of listed companies for the first half of the year is 52.4665 million yuan to 58.2961 million yuan, down 50%-55% from the previous year. Net profit after deducting non-recurring profit and loss is estimated to be 108.784 million yuan to 152,297 million yuan, down 86%-90% from the previous year. Reason for the change in performance: Due to factors such as continued interest rate hikes in the US dollar, overseas market demand was weak. Sales volume and price of the company's main product tauric acid declined year-on-year in the first half of the year, resulting in operating income and net profit
Yongan Pharma Registers New Health Food Products
Qianjiang Yongan Pharmaceutical (SHE:002365) has obtained a registration certificate for its new health food products, according to a filing on Tuesday. The approval was handed down by China's State A
Analysis
Price Target
No Data
